Cargando…
Reduced-intensity, risk factor–stratified immunosuppression for acquired hemophilia A: single-center observational study
Immunosuppressive therapy (IST) is administered to patients with acquired hemophilia A (AHA) to eradicate autoantibodies against coagulation factor VIII (FVIII). Data from registries previously demonstrated that IST is often complicated by adverse events, in particular infections. This pilot study w...
Autores principales: | Dobbelstein, Christiane, Moschovakis, Georgios Leandros, Tiede, Andreas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7419459/ https://www.ncbi.nlm.nih.gov/pubmed/32621181 http://dx.doi.org/10.1007/s00277-020-04150-y |
Ejemplares similares
-
Acquired Hemophilia Successfully Treated With Oral Immunosuppressive Therapy
por: Lee, Je Jung, et al.
Publicado: (2000) -
The Treatment of Acquired Hemophilia with Combination Therapy of Immunosuppressives and Immunoadsorption
por: Uğur Bilgin, Aynur, et al.
Publicado: (2014) -
Immunosuppression Therapy in Acquired Hemophilia A: Pursuing an Optimal Regimen
por: Teixeira Passos, Dúlio, et al.
Publicado: (2021) -
International recommendations on the diagnosis and treatment of acquired hemophilia A
por: Tiede, Andreas, et al.
Publicado: (2020) -
Acquired Hemophilia
por: Özsoylu, Şinasi
Publicado: (2014)